ArticleHIV medicine2026
HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesIncreasing rates of HIV-1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub-Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options. The Republic of Congo (ROC) lacks comprehensive national data on HIVDR in these vulnerable populations. The study aimed to determine the proportion of virologically unsuppressed young individuals receiving ART in ROC and to characterize the prevalence and patterns of HIVDR.
methodsA point prevalence analysis was conducted in Pointe-Noire to determine viral load and to characterize resistance-associated mutations (RAMs) in HIV-1 among children, adolescents and young adults receiving ART using next-generation sequencing. Sociodemographic and clinical data were collected to assess associations between resistance, treatment history and adherence. Ethical approval was obtained (Avis n° 034/CIE/FCRM/2021).
resultsA total of 510 participants were included, with a median age of 19.5 (IQR 13-40) and a median CD4 T-cell count of 538/μl (IQR 279-901). Among them, 34% (n = 173) had detectable viral loads (> 40 copies/ml) while on ART. Of the viremic cohort, 147 samples were successfully sequenced and showed diverse HIV subtypes, with subtype A1 (21%) being the most prevalent. Drug resistance was most frequently observed against NRTIs and NNRTIs, with M184V (54.1%) and K103N (40.8%) mutations predominating. Resistance to protease inhibitors was rare. Notably, no major resistance was found to integrase inhibitors or capsid inhibitors.
conclusionsHIV-1 drug resistance is highly prevalent in young people receiving ART in the ROC. This study highlights the urgent need to integrate HIVDR genotyping into clinical practice in the ROC to guide treatment and preserve future treatment options. Strengthened adherence support, resistance testing at treatment failure and equitable access to newer antiretroviral drugs are essential to sustain treatment effectiveness and support progress toward the 2030 global HIV targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.